Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2

Interventions

Cyclophosphamide 62Rituximab 52fludarabine 34Prednisone 34Doxorubicin 29Vincristine 26Biopsy 26Specimen Handling 22Magnetic Resonance Spectroscopy 20Bendamustine Hydrochloride 19pembrolizumab 17Lenalidomide 17obinutuzumab 14fludarabine phosphate 14Etoposide 14venetoclax 13Tacrolimus 11Mycophenolic Acid 10Melphalan 10Dexamethasone 10zanubrutinib 9ibrutinib 9acalabrutinib 9Radiotherapy 9Gemcitabine 9Cytarabine 9Busulfan 9Whole-Body Irradiation 8Mesna 8Filgrastim 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma × ibritumomab tiuxetan × 1 year × Clear all
NCT00690560 2026-05-22

Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

Centre Antoine Lacassagne

Phase 2 Completed
30 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT01359592 2025-06-17

S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

SWOG Cancer Research Network

Phase 2 Completed
159 enrolled 21 charts
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡